Treatment for Ovarian Cancer

Cancer Education and Research Institute (CERI)'s Cancer Education Programs

Rubraca (rucaparib):

On December 19, 2016, the U.S. Food and Drug Administration (FDA) has approved Rubraca (rucaparib) to treat women with advanced ovarian cancer that has BRCA gene mutation.

BRCA genes are involved with repairing damaged DNA. Thus, under normal conditions, they work to prevent tumor development. However, mutations (abnormalities) of these genes may lead to certain cancers, which include breast and ovarian cancers. Rubraca is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme (a protein involved in catalytic reactions in our body), which is involved in repairing damaged DNA. By blocking this enzyme through Rubraca, DNA inside the cancerous cells with damaged/mutated/abnormal BRCA genes may be less likely to be repaired by the enzyme, which leads to cell death and potentially a slow-down or inhibition of tumor growth.

Common side effects of Rubraca include nausea, fatigue, vomiting, low levels of red blood cells (anemia), abdominal pain, unusual taste sensation (dysgeusia), constipation, decreased appetite, diarrhea, low levels of blood platelets (thrombocytopenia) and trouble breathing (dyspnea). Rubraca is associated with serious risks, such as bone marrow problems (myelodysplastic syndrome), a type of cancer of the blood called acute myeloid leukemia and fetal harm.

Rubraca is marketed by Clovis Oncology, Inc. based in Boulder, Colorado. The FoundationFocus CDxBRCA companion diagnostic is marketed by Foundation Medicine, Inc. of Cambridge, Massachusetts.

For more information visit the FDA's website: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm

To learn more about ovarian cancer, read our articles, watch our videos:

#ovariancancer #womenshealth #BRCA #gene #rubraca #rucaparib #FDA #FDAapproval #ovariancancertreatment #cancertreatment #health #cancer #cancerpatients #cancereducation #patienteducation #publiceducation #canceredinstitute

Did you find this article helpful? Please let us know below. Be sure to share it with your loved ones.

You might also like:

Disclaimer: We can not assume responsibility of misinterpretation of content.

👉 Like our Facebook page for daily cancer info: Cancer Education and Research Institute
👉#canceredinstitute

Cancer Education and Research Institute® (CERI)'s, formerly Cancer Research Simplified, mission is simple: Cancer Education for All™! Our Team of cancer experts provides you with the most reliable, most up-to-date, and simplified cancer information available. Our educational programs quickly became trusted and highly sought after worldwide.

CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education. Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.

For any questions or requests, please contact us.

Please donate to support our cause - help us continue with our trusted educational programs;
help us save lives; help us guide and empower cancer patients and their caregivers:

Cancer Education and Research Institute, fka Cancer Research Simplified, is a registered 501(c)(3) non-profit organization.
Your donations are tax deductible to the extent permitted by law.

Cancer Education and Research Institute (CERI)'s Cancer Education Programs